Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).

Trial Details

NCT ID
NCT05846750
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • Obinutuzumab
  • lenalidomide
Locations (sample)
  • Tianjin, Tian, China|39.14222,117.17667

Key Eligibility Criteria

  • Signed Informed Consent Form
  • Age ≥18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Histologically confirmed MZL. have a definite diagnosis of MZL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →